Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Informational only. Not medical advice.INFORMATIONAL PLATFORM ONLY — NOT MEDICAL ADVICE, DIAGNOSIS, OR TREATMENT
Head-to-head comparison of AHK-Cu and KPV — mechanism, side effects, legal status, and pricing.
AHK-Cu is a copper-binding tripeptide (Ala-His-Lys-Cu) structurally related to GHK-Cu, studied in dermatological research for its role in extracellular matrix remodeling and hair follicle signaling.
KPV (Lys-Pro-Val) is the C-terminal tripeptide of alpha-melanocyte-stimulating hormone (alpha-MSH residues 11-13), the smallest alpha-MSH fragment retaining anti-inflammatory activity. Research-only; not FDA-approved. Evidence is primarily preclinical with no controlled human trials.
AHK-Cu
KPV
Category
Legal Status
Mechanism
Half-life
Side Effects
COA-verified vendors · trust score ≥70 required · single-vial price — bulk/bundle deals may be lower
AHK-Cu
KPV
COA corpus from Disclosed Labs — independently tested batches only.
AHK-Cu
14
COAs
99.6%
Avg purity
5
Labs
KPV
89
COAs
99.5%
Avg purity
15
Labs
Pyo et al. (Archives of Pharmacal Research, 2007) reported that AHK-Cu stimulated elongation of human hair follicles ex vivo, promoted proliferation of dermal papilla cells, and increased VEGF secretion while reducing TGF-beta1 in cultured fibroblasts. Evidence is preclinical only; no controlled clinical trials have been published.
Dalmasso et al. (Gastroenterology 2008; PMID 18061177) demonstrated PepT1-mediated uptake of KPV and reduction of DSS- and TNBS-induced colitis in mice. Kannengiesser et al. (Inflammatory Bowel Diseases 2008; PMID 18092346) showed anti-inflammatory effects in two murine colitis models at least partly independent of MC1R signaling. Brzoska et al. (Endocrine Reviews 2008; PMID 18612139) reviewed alpha-MSH and related tripeptides, summarizing NF-kB suppression across cell types. Subsequent preclinical work (largely from the Merlin group at Georgia State) has explored oral nanoparticle and polysaccharide-hydrogel delivery for IBD. No controlled human trials have been published.
Key references
AHK-Cu (Cosmetic) and KPV (Immune) are in different categories and target different biological pathways. This is a common pattern in multi-compound research protocols. Researchers should monitor the biomarkers from both profiles and watch for interactions listed in each compound’s contraindications. Consult a licensed healthcare provider before combining any research compounds.
This platform provides informational tools only, not medical advice. This comparison is for educational purposes only. Consult a licensed provider.
Contraindications
Lab Testing
Disclosed Labs